adenosine diphosphate ribose has been researched along with platinum in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Au-Yeung, G; Freimund, A; Friedlander, M; Krasovitsky, M; Lee, YC; Mileshkin, L; Norris, C; Sivakumaran, T; So, J; Webber, K | 1 |
| Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A | 1 |
| Chen, SC; Lai, YH; Tung, KC | 1 |
| Chen, X; Dong, S; Hou, D; Li, H; Peng, Y; Wang, H | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
1 trial(s) available for adenosine diphosphate ribose and platinum
| Article | Year |
|---|---|
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms | 2023 |
4 other study(ies) available for adenosine diphosphate ribose and platinum
| Article | Year |
|---|---|
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Retrospective Studies | 2022 |
Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.
Topics: Adenosine Diphosphate Ribose; Adult; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cisplatin; Fanconi Anemia Complementation Group A Protein; Female; Humans; Liver Neoplasms; Male; Mutation; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1.
Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Membrane Proteins; Microtubule-Associated Proteins; Microtubules; Platinum; Prognosis; Tumor Microenvironment | 2022 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |